Publication:
Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature

Simple item page
dc.contributor.authorSALMAN, ANDAÇ
dc.contributor.authorAKTAŞ, MERYEM
dc.contributor.authorsSalman, Andac; Aktas, Meryem
dc.date.accessioned2022-03-10T11:39:44Z
dc.date.accessioned2026-01-11T13:39:32Z
dc.date.available2022-03-10T11:39:44Z
dc.date.issued2021-08-23
dc.description.abstractOmalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented.
dc.identifier.doi10.21911/aai.599
dc.identifier.issn1308-9234
dc.identifier.urihttps://hdl.handle.net/11424/219909
dc.identifier.wosWOS:000687772900010
dc.language.isoeng
dc.publisherBILIMSEL TIP YAYINEVI
dc.relation.ispartofASTIM ALLERJI IMMUNOLOJI
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectChronic spontaneous urticaria
dc.subjectomalizumab
dc.subjectpregnancy
dc.subjectupdosing
dc.titleOmalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage117
oaire.citation.issue2
oaire.citation.startPage114
oaire.citation.titleASTIM ALLERJI IMMUNOLOJI
oaire.citation.volume19

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
392.73 KB
Format:
Adobe Portable Document Format
Download

Collections

Araştırma Çıktıları